Summary:
«With a Takeda collaboration already in its pocket, Ensoma announced a $70 million Series A round to help develop its platform of engineered gene therapy vectors for off-the-shelf in vivo therapeutics, starting in rare diseases.»
«Ensoma is developing helper-dependent adenoviral vectors–vectors with viral coding sequences removed–that would not be limited to ex vivo editing for autologous cell therapies or require myeloablative conditioning to prepare a patient’s immune system.»
Article written by Mark Zipkin
11|02|2021
Source:
Bio Space